BLADE THERAPEUTICS

Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package

Retrieved on: 
星期一, 四月 4, 2022
Research, Mental Health, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Risk, Therapy, Fibrosis, Biomarker, Cayman Islands, Neurodegeneration, Liver, SEC, Probability, CEO, IPF, Knowledge, Securities Act of 1933, Matrix, Business architecture, BIOT, Autotaxin, Disease, Bristol Myers Squibb, Proxy, Sale, Trial of the century, Kidney, Myofibroblast, Vital capacity, Aggregation, NASH, Combined, NASDAQ, Lung, Form, Investment, Transaction, Forward-looking statement, Mortality, LPA, BAC, Failure, Prospectus, POC, FDA, Interstitial lung disease, Patient, Company, LinkedIn, Institute of Liver and Biliary Sciences, HIV disease progression rates, PIPE, Safety, COVID-19, Acquisition, Pharmaceutical industry, Financial services, Security (finance), Audit, Risk management, Nasdaq, Blade, Target, BLADE THERAPEUTICS, BIOTECH ACQUISITION COMPANY

The FDA response letter outlined requirements for a proposed phase 2 PoC/dose ranging study for use of cudetaxestat in patients with IPF.

Key Points: 
  • The FDA response letter outlined requirements for a proposed phase 2 PoC/dose ranging study for use of cudetaxestat in patients with IPF.
  • We are pleased with the guidance provided by the FDA, said Wendye Robbins, M.D., president and CEO of Blade.
  • Available data from completed phase 1 studies in healthy volunteers showed that cudetaxestat was well tolerated with a demonstrated pharmacokinetic/pharmacodynamic correlation and biomarker activity.
  • Cudetaxestat is an investigational medicine that is not approved for commercial use by the FDA or any other regulatory authority.

Blade Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
星期一, 三月 7, 2022
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Risk, Failure, Cayman Islands, BIOT, Fibrosis, HIV disease progression rates, Investment, Interstitial lung disease, Forward-looking statement, Matrix, Neurodegeneration, Disease, Myofibroblast, Prospectus, LinkedIn, Combined, Therapy, SEC, Bristol Myers Squibb, Blade, BAC, Company, COVID-19, Aggregation, Institute of Liver and Biliary Sciences, Form, Securities Act of 1933, Conference, NASH, CEO, Acquisition, Transaction, IPF, PIPE, Business architecture, Lung, Sale, Liver, Kidney, Mortality, LPA, Probability, Proxy, NASDAQ, Pharmaceutical industry, Financial services, Security (finance), Audit, Risk management, Target, Nasdaq, Blade Therapeutics, Biotech Acquisition Company, Blade Therapeutics, Biotech Acquisition Company, BLADE THERAPEUTICS, BIOTECH ACQUISITION COMPANY

Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will present at two investor conferences in March.

Key Points: 
  • Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will present at two investor conferences in March.
  • ET, in Miami
    Blade Therapeutics, Inc. is a biopharmaceutical company focused on developing cutting-edge treatments for debilitating, incurable fibrotic and neurodegenerative diseases that impact millions of people worldwide.
  • Upon the closing of the transaction, the combined company will be renamed Blade Biotherapeutics, Inc., and is expected to be listed on Nasdaq under the symbol BBTX.
  • PIPE financing is anchored by leading institutional investors, including Deerfield Management, Pfizer Ventures, Bristol Myers Squibb, MPM Capital and Osage University Partners.